Last reviewed · How we verify

Vivag Plus — Competitive Intelligence Brief

Vivag Plus (Vivag Plus) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sulfonylurea and meglitinide combination. Area: Diabetes.

marketed Sulfonylurea and meglitinide combination Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Vivag Plus (Vivag Plus) — Zealand University Hospital. Vivag Plus is a combination of two medications that work together to lower blood sugar levels.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Vivag Plus TARGET Vivag Plus Zealand University Hospital marketed Sulfonylurea and meglitinide combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sulfonylurea and meglitinide combination class)

  1. Zealand University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vivag Plus — Competitive Intelligence Brief. https://druglandscape.com/ci/vivag-plus. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: